Alsmadi MM - Search Results

1

Delivery of Peptidic Gonadotropin Releasing Hormone Antagonists.

AlSheyyab RY, Al-Taani BM, Obeidat RM, Alsmadi MM, Masaedeh RK, Sabat RN. AlSheyyab RY, et al. Among authors: alsmadi mm. Curr Drug Deliv. 2018;15(5):602-609. doi: 10.2174/1567201815666180214142300. Curr Drug Deliv. 2018. PMID: 29446744 Review.

2

Development and Evaluation of Cocoa Butter Taste Masked Ibuprofen Using Supercritical Carbon Dioxide.

Obaidat R, Aleih H, Mashaqbeh H, Altaani B, Alsmadi MM, Alnaief M. Obaidat R, et al. Among authors: alsmadi mm. AAPS PharmSciTech. 2021 Mar 14;22(3):106. doi: 10.1208/s12249-021-01962-7. AAPS PharmSciTech. 2021. PMID: 33719021

3

Sublingual spray drug delivery of ketorolac-loaded chitosan nanoparticles.

Baltzley S, Malkawi AA, Alsmadi M, Al-Ghananeem AM. Baltzley S, et al. Drug Dev Ind Pharm. 2018 Sep;44(9):1467-1472. doi: 10.1080/03639045.2018.1460378. Epub 2018 Apr 12. Drug Dev Ind Pharm. 2018. PMID: 29607693

4

Optimization of Drugs Pharmacotherapy During Pregnancy Using Physiologically Based Pharmacokinetic Models - An Update.

Alsmadi MM, Idkaidek N. Alsmadi MM, et al. Curr Drug Metab. 2018;19(12):972-978. doi: 10.2174/1389200219666180702104034. Curr Drug Metab. 2018. PMID: 29962340 Review.

5

Saliva versus Plasma Therapeutic Drug Monitoring of Gentamicin in Jordanian Preterm Infants. Development of a Physiologically-Based Pharmacokinetic (PBPK) Model and Validation of Class II Drugs of Salivary Excretion Classification System.

Idkaidek N, Hamadi S, Bani-Domi R, Al-Adham I, Alsmadi M, Awaysheh F, Aqrabawi H, Al-Ghazawi A, Rabayah A. Idkaidek N, et al. Drug Res (Stuttg). 2020 Oct;70(10):455-462. doi: 10.1055/a-1233-3582. Epub 2020 Sep 2. Drug Res (Stuttg). 2020. PMID: 32877949

6

The development of a population physiologically based pharmacokinetic model for mycophenolic mofetil and mycophenolic acid in humans using data from plasma, saliva, and kidney tissue.

Alsmadi MM, Alfarah MQ, Albderat J, Alsalaita G, AlMardini R, Hamadi S, Al-Ghazawi A, Abu-Duhair O, Idkaidek N. Alsmadi MM, et al. Biopharm Drug Dispos. 2019 Nov;40(9):325-340. doi: 10.1002/bdd.2206. Epub 2019 Nov 15. Biopharm Drug Dispos. 2019. PMID: 31674040

7

Development, In Vitro Characterization, and In Vivo Toxicity Evaluation of Chitosan-Alginate Nanoporous Carriers Loaded with Cisplatin for Lung Cancer Treatment.

Alsmadi MM, Obaidat RM, Alnaief M, Albiss BA, Hailat N. Alsmadi MM, et al. AAPS PharmSciTech. 2020 Jul 13;21(5):191. doi: 10.1208/s12249-020-01735-8. AAPS PharmSciTech. 2020. PMID: 32661587

8

Physiologically-based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment.

Alsmadi MM, Al-Daoud NM, Jaradat MM, Alzughoul SB, Abu Kwiak AD, Abu Laila SS, Abu Shameh AJ, Alhazabreh MK, Jaber SA, Abu Kassab HT. Alsmadi MM, et al. Biopharm Drug Dispos. 2021 Jun;42(6):263-284. doi: 10.1002/bdd.2282. Epub 2021 May 5. Biopharm Drug Dispos. 2021. PMID: 33904202

9

The investigation of the complex population-drug-drug interaction between ritonavir-boosted lopinavir and chloroquine or ivermectin using physiologically-based pharmacokinetic modeling.

Alsmadi MM. Alsmadi MM. Drug Metab Pers Ther. 2022 Oct 10;38(1):87-105. doi: 10.1515/dmpt-2022-0130. eCollection 2023 Mar 1. Drug Metab Pers Ther. 2022. PMID: 36205215

10

In vitro-in vivo extrapolation of bexarotene metabolism in the presence of chronic kidney disease and acute kidney injury in rat using physiologically based pharmacokinetic modeling and extrapolation to human.

Alsmadi MM, Alzughoul SB. Alsmadi MM, et al. Biopharm Drug Dispos. 2023 Jun;44(3):221-244. doi: 10.1002/bdd.2337. Epub 2022 Nov 21. Biopharm Drug Dispos. 2023. PMID: 36319070

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

26 results

Search Page